JP2024540085A5 - - Google Patents

Info

Publication number
JP2024540085A5
JP2024540085A5 JP2024525344A JP2024525344A JP2024540085A5 JP 2024540085 A5 JP2024540085 A5 JP 2024540085A5 JP 2024525344 A JP2024525344 A JP 2024525344A JP 2024525344 A JP2024525344 A JP 2024525344A JP 2024540085 A5 JP2024540085 A5 JP 2024540085A5
Authority
JP
Japan
Prior art keywords
factor
item
coding sequence
protein
protein coding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024525344A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540085A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/078798 external-priority patent/WO2023077012A1/en
Publication of JP2024540085A publication Critical patent/JP2024540085A/ja
Publication of JP2024540085A5 publication Critical patent/JP2024540085A5/ja
Pending legal-status Critical Current

Links

JP2024525344A 2021-10-27 2022-10-27 血友病b療法のための第ix因子を発現させるための組成物及び方法 Pending JP2024540085A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163272324P 2021-10-27 2021-10-27
US63/272,324 2021-10-27
US202263306037P 2022-02-02 2022-02-02
US63/306,037 2022-02-02
US202263369864P 2022-07-29 2022-07-29
US63/369,864 2022-07-29
PCT/US2022/078798 WO2023077012A1 (en) 2021-10-27 2022-10-27 Compositions and methods for expressing factor ix for hemophilia b therapy

Publications (2)

Publication Number Publication Date
JP2024540085A JP2024540085A (ja) 2024-10-31
JP2024540085A5 true JP2024540085A5 (cg-RX-API-DMAC7.html) 2025-10-30

Family

ID=84439883

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024525344A Pending JP2024540085A (ja) 2021-10-27 2022-10-27 血友病b療法のための第ix因子を発現させるための組成物及び方法

Country Status (12)

Country Link
US (1) US20230149563A1 (cg-RX-API-DMAC7.html)
EP (1) EP4423119A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024540085A (cg-RX-API-DMAC7.html)
KR (1) KR20240099358A (cg-RX-API-DMAC7.html)
AU (1) AU2022379633A1 (cg-RX-API-DMAC7.html)
CA (1) CA3232470A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001251A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024005281A2 (cg-RX-API-DMAC7.html)
IL (1) IL312000A (cg-RX-API-DMAC7.html)
MX (1) MX2024005124A (cg-RX-API-DMAC7.html)
TW (1) TW202334194A (cg-RX-API-DMAC7.html)
WO (1) WO2023077012A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024315073A1 (en) * 2023-07-28 2026-01-22 Regeneron Pharmaceuticals, Inc. Use of bgh-sv40l tandem polya to enhance transgene expression during unidirectional gene insertion
US20250242056A1 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2025265017A1 (en) * 2024-06-20 2025-12-26 Regeneron Pharmaceuticals, Inc. Ass1 gene insertion for the treatment of citrullinemia type i
WO2026100298A1 (ja) * 2024-11-06 2026-05-15 学校法人自治医科大学 ポリヌクレオチド、ベクター、血友病b治療用組成物、脂質ナノ粒子、細胞生成方法、及び血友病b治療方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE347593T1 (de) 2002-01-23 2006-12-15 Univ Utah Res Found Zielgerichtete chromosomale mutagenese mit zinkfingernukleasen
EP1504092B2 (en) 2002-03-21 2014-06-25 Sangamo BioSciences, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
US9447434B2 (en) 2002-09-05 2016-09-20 California Institute Of Technology Use of chimeric nucleases to stimulate gene targeting
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
KR20070060115A (ko) 2004-09-16 2007-06-12 상가모 바이오사이언스 인코포레이티드 단백질 생산을 위한 조성물 및 방법
EP2027262B1 (en) 2006-05-25 2010-03-31 Sangamo Biosciences Inc. Variant foki cleavage half-domains
US7951925B2 (en) 2006-05-25 2011-05-31 Sangamo Biosciences, Inc. Methods and compositions for gene inactivation
EP2108045B1 (en) 2007-02-01 2013-12-11 Baxter International Inc. Improved fix-mutant proteins for hemophilia b treatment
US8022187B2 (en) 2007-02-01 2011-09-20 Baxter International Inc. FVIII-independent FIX-mutant proteins for hemophilia A treatment
US8110379B2 (en) 2007-04-26 2012-02-07 Sangamo Biosciences, Inc. Targeted integration into the PPP1R12C locus
CA2720903C (en) 2008-04-14 2019-01-15 Sangamo Biosciences, Inc. Linear donor constructs for targeted integration
EP2149603A1 (en) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
JP5908725B2 (ja) 2008-08-22 2016-04-26 サンガモ バイオサイエンシーズ, インコーポレイテッド 標的一本鎖開裂および標的組込みのための方法、並びに組成物
US9255259B2 (en) 2010-02-09 2016-02-09 Sangamo Biosciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
US9567573B2 (en) 2010-04-26 2017-02-14 Sangamo Biosciences, Inc. Genome editing of a Rosa locus using nucleases
AU2011256838B2 (en) 2010-05-17 2014-10-09 Sangamo Therapeutics, Inc. Novel DNA-binding proteins and uses thereof
EP2758529B1 (en) 2011-09-21 2019-03-20 Sangamo Therapeutics, Inc. Methods and compositions for regulation of transgene expression
US9222105B2 (en) 2011-10-27 2015-12-29 Sangamo Biosciences, Inc. Methods and compositions for modification of the HPRT locus
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
EP2881463A1 (en) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
CA3229275A1 (en) * 2013-12-09 2015-06-18 Sangamo Biosciences, Inc. Methods and compositions for genome engineering
EP4378487A3 (en) * 2015-06-23 2024-09-04 The Children's Hospital of Philadelphia Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
TWI753168B (zh) * 2017-05-22 2022-01-21 日商武田藥品工業股份有限公司 用於血友病b基因療法之編碼具有增強表現的重組fix變異體之病毒載體
JP7119009B2 (ja) * 2017-05-31 2022-08-16 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 最適化されたヒト凝固第ix因子遺伝子発現カセットおよびそれらの使用
AU2019323747A1 (en) * 2018-08-20 2021-03-04 Ucl Business Ltd Factor ix encoding nucleotides
CN113272428A (zh) 2018-10-18 2021-08-17 英特利亚治疗股份有限公司 核酸构建体和使用方法
JP7578590B2 (ja) 2018-10-18 2024-11-06 インテリア セラピューティクス,インコーポレーテッド 第ix因子を発現するための組成物及び方法
BR112021007343A2 (pt) 2018-10-18 2021-08-03 Intellia Therapeutics, Inc. composições e métodos para expressão de transgene a partir de um lócus de albumina
WO2020160303A1 (en) * 2019-02-01 2020-08-06 Baxalta Incorporated Gene therapy of hemophilia b using viral vectors encoding recombinant fix variants with increased expression
ES3062513T3 (en) * 2019-03-19 2026-04-13 CSL Innovation Pty Ltd Factor ix variants and uses thereof in therapy

Similar Documents

Publication Publication Date Title
US12234449B2 (en) CRISPR/Cas-related methods and compositions for treating Leber's congenital amaurosis 10 (LCA10)
EP3368560B1 (en) Cpg reduced factor viii variants, compositions and methods and uses for treatment of hemostasis disorders
US20260125677A1 (en) Compositions and Methods for Treating Alpha-1 Antitrypsin Deficiency
JP2025508677A5 (cg-RX-API-DMAC7.html)
JP6642943B2 (ja) 血友病を処置するための方法および組成物
EP3180022B1 (en) An improved expression cassette for packaging and expression of variant factor viii for the treatment of hemostasis disorders
JP7473548B2 (ja) Mmaの処置のための非破壊的遺伝子治療
CA3017956A1 (en) Crispr/cas-related methods and compositions for treating beta hemoglobinopathies
WO2015157070A2 (en) Crispr/cas-related methods and compositions for treating cystic fibrosis
WO2015153780A1 (en) Crispr/cas-related methods and compositions for treating primary open angle glaucoma
US20230149563A1 (en) Compositions and methods for expressing factor ix for hemophilia b therapy
Ohmori et al. New approaches to gene and cell therapy for hemophilia
JP2020527030A (ja) 肝臓において目的のタンパク質を発現するためのプラットフォーム
JP2022553573A5 (cg-RX-API-DMAC7.html)
CA3108376A1 (en) Compositions and methods for treating cep290-associated disease
US11634726B2 (en) Cas9 nucleic acid molecules and their use
JP2025514304A5 (cg-RX-API-DMAC7.html)
KR102847166B1 (ko) 항응고 인자들의 유전자 에디팅
CN112041437A (zh) 用于恢复f8基因功能的腺相关病毒组合物和其使用方法
US20230190889A1 (en) Gene editing of anticoagulant factors
CN117980482A (zh) Rbm20突变的基因组编辑
US20200263204A1 (en) Composition for treating hemophilia a by crispr/cas system of reverting fviii gene inversion
US20260002151A1 (en) Compositions and methods for the modification and regulation of liver gene expression
US20240325454A1 (en) Genomic editing of rbm20 mutations
AU779514B2 (en) Methods and compositions for use in gene therapy for treatment of hemophilia